The Therapeutic Aspects of the Endocannabinoid System (ECS) for Cancer and their Development: From Nature to Laboratory

Author(s): Mohammed I. Khan, Anna A. Sobocińska, Anna M. Czarnecka, Magdalena Król, Bruno Botta, Cezary Szczylik.

Journal Name:Current Pharmaceutical Design

Volume 22 , Issue 12 , 2016

Abstract:

The endocannabinoid system (ECS) is a group of neuromodulatory lipids and their receptors, which are widely distributed in mammalian tissues. ECS regulates various cardiovascular, nervous, and immune system functions inside cells. In recent years, there has been a growing body of evidence for the use of synthetic and natural cannabinoids as potential anticancer agents. For instance, the CB1 and CB2 receptors are assumed to play an important role inside the endocannabinoid system. These receptors are abundantly expressed in the brain and fatty tissue of the human body. Despite recent developments in molecular biology, there is still a lack of knowledge about the distribution of CB1 and CB2 receptors in the human kidney and their role in kidney cancer. To address this gap, we explore and demonstrate the role of the endocannabinoid system in renal cell carcinoma (RCC). In this brief overview, we elucidate the therapeutic aspects of the endocannabinoid system for various cancers and explain how this system can be used for treating kidney cancer. Overall, this review provides new insights into cannabinoids’ mechanisms of action in both in vivo and in vitro models, and focuses on recent discoveries in the field.

Keywords: CB1 and CB2 receptors, Cannabinoids, Endocannabinoid system, Renal cell carcinoma.

Rights & PermissionsPrintExport

Article Details

VOLUME: 22
ISSUE: 12
Year: 2016
Page: [1756 - 1766]
Pages: 11
DOI: 10.2174/1381612822666151211094901

Article Metrics

PDF: 34
HTML: 0
EPUB: 0
PRC: 0